Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14644928 | 1.00 | TSHR (0.45) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL1357542 | 0.97 | TSHR (0.47) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL19543524 | 0.95 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL18251591 | 0.92 | MEN1 (0.55) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL18251590 | 0.92 | MEN1 (0.55) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL13563001 | 0.91 | TSHR (0.48) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL12317010 | 0.90 | MEN1 (0.52) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL11965453 | 0.90 | MEN1 (0.52) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL19543624 | 0.87 | MEN1 (0.55) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL21855423 | 0.87 | MEN1 (0.55) | TSHRMAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501998-B2 | Method for producing polyoxyalkylene derivative and polyoxyalkylene derivative | NOF CORPORATION (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8367065-B2 | Targeted polymeric prodrugs containing multifunctional linkers | ENZON PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8299089-B2 | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers | ENZON PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8268318-B2 | Polyalkylene oxides having hindered ester-based biodegradable linkers | ENZON PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120171201-A1 | METHODS OF TREATING HER2 POSITIVE CANCER WITH HER2 RECEPTOR ANTAGONIST IN COMBINATION WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN | ENZON PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120122956-A1 | METHODS FOR INHIBITING ANGIOGENESIS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN | ENZON PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8110559-B2 | Hindered ester-based biodegradable linkers for oligonucleotide delivery | ENZON PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8071741-B2 | Stable recombinant adenosine deaminase | DEFIANTE FARMACEUTICA, S.A. (PT) | 2011-12-06 | — | — | US | disclosed |
| US-20110195990-A1 | TREATMENT OF RESISTANT OR REFRACTORY CANCERS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN | ENZON PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-7928095-B2 | DNA topoisomerase I inhibitors; anticancer agents | ENZON PHARMACEUTICALS, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100056555-A1 | METHOD OF TREATING RAS ASSOCIATED CANCER | ENZON PHARMACEUTICALS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090232833-A1 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090202573-A1 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | ENZON PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090047271-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | ENZON PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090017004-A1 | POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID | ENZON PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090016985-A1 | POLYMERIC DRUG DELIVERY SYSTEM CONTAINING A MULTI-SUBSTITUTED AROMATIC MOIETY | ENZON PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-7462627-B2 | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers | ENZON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080193408-A1 | TREATMENT OF RESISTANT OR REFRACTORY CANCERS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN | ENZON PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080159964-A1 | USE OF ADENOSINE DEAMINASE FOR TREATING PULMONARY DISEASE | ENZON PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070197575-A1 | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers | BELROSE PHARMA INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080159964-A1 | USE OF ADENOSINE DEAMINASE FOR TREATING PULMONARY DISEASE | ADA, AMPD2, AMPD1 | TSHR 3259/4885MAPK1 4787/4885MEN1 4872/4885 |
| US-20120122956-A1 | METHODS FOR INHIBITING ANGIOGENESIS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN | VEGFA, FLT4, FLT1 | TSHR 4665/4885MAPK1 4578/4885MEN1 1869/4885 |
| US-20090017004-A1 | POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID | AADAC, ACSS2, ANXA6 | TSHR 2587/4885MAPK1 4791/4885MEN1 4801/4885 |
| US-20090202573-A1 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | PIGO, PHOSPHO1, PAICS | TSHR 2293/4885MAPK1 4714/4885MEN1 2681/4885 |
| US-20090016985-A1 | POLYMERIC DRUG DELIVERY SYSTEM CONTAINING A MULTI-SUBSTITUTED AROMATIC MOIETY | ABCB1, PAICS, ABCG2 | TSHR 2512/4885MAPK1 4800/4885MEN1 4578/4885 |
| US-20070197575-A1 | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers | TOP2A, CASP10, CASP7 | TSHR 3979/4885MAPK1 4816/4885MEN1 453/4885 |
| US-20090232833-A1 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS | CES2, PLOD3, FASN | TSHR 3488/4885MAPK1 4787/4885MEN1 4022/4885 |
| US-20110195990-A1 | TREATMENT OF RESISTANT OR REFRACTORY CANCERS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN | TOP2A, FOLR1, TOP1 | TSHR 3641/4885MAPK1 4717/4885MEN1 1082/4885 |
| US-20120171201-A1 | METHODS OF TREATING HER2 POSITIVE CANCER WITH HER2 RECEPTOR ANTAGONIST IN COMBINATION WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN | ERBB2, ERBB3, EGFR | TSHR 1025/4885MAPK1 3427/4885MEN1 2557/4885 |
| US-20090047271-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | ADA, CDA, DCTD | TSHR 2145/4885MAPK1 4573/4885MEN1 2644/4885 |
| US-20100056555-A1 | METHOD OF TREATING RAS ASSOCIATED CANCER | KRAS, HRAS, NRAS | TSHR 3219/4885MAPK1 1394/4885MEN1 1012/4885 |
| US-20080193408-A1 | TREATMENT OF RESISTANT OR REFRACTORY CANCERS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN | TOP2A, FOLR1, TOP1 | TSHR 3641/4885MAPK1 4717/4885MEN1 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.